We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+23.18%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$830M
AUM Growth
+$42.8M
Cap. Flow
-$37.4M
Cap. Flow %
-4.51%
Top 10 Hldgs %
61.35%
Holding
46
New
10
Increased
9
Reduced
10
Closed
4

Top Buys

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$50.9M
2
SNDX icon
Syndax Pharmaceuticals
SNDX
+$32M
3
ARRY
Array Biopharma Inc
ARRY
+$26M
4
OMED
OncoMed Pharmaceuticals, Inc.
OMED
+$18.6M
5
PHXM
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
+$14.8M

Top Sells

Rank Stock Value
1
ANAB icon
AnaptysBio
ANAB
+$57.8M
2
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$44.5M
3
CBIO
Crescent Biopharma
CBIO
+$36.1M
4
CNCE
Concert Pharmaceuticals, Inc.
CNCE
+$23.5M
5
CTMX icon
CytomX Therapeutics
CTMX
+$22.9M

Sector Composition

Rank Sector Weight
1 Healthcare 85.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CBIO
26
Crescent Biopharma
CBIO
$555M
$8.35M 1.01%
4,975
-27,324
-85% -$36.1M
ALPN
27
DELISTED
Alpine Immune Sciences Inc
ALPN
$7.57M 0.91%
675,759
– –
VIRX
28
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$7.54M 0.91%
58,377
– –
MTEM
29
DELISTED
Molecular Templates, Inc.
MTEM
$7.26M 0.87%
48,275
– –
VSTM icon
30
Verastem
VSTM
$536M
$6.91M 0.83%
+187,500
New +$8.47M
PTGX icon
31
Protagonist Therapeutics
PTGX
$8.92B
$6.12M 0.74%
+294,117
New +$5.22M
IMDZ
32
DELISTED
Immune Design Corp.
IMDZ
$5.73M 0.69%
+1,469,800
New +$8M
FBRX icon
33
Forte Biosciences
FBRX
$1.58B
$5.71M 0.69%
1,484
-1,351
-48% -$5.39M
CRVS icon
34
Corvus Pharmaceuticals
CRVS
$1.11B
$4.76M 0.57%
459,396
– –
ACHN
35
DELISTED
Achillion Pharmaceuticals
ACHN
$4.63M 0.56%
+1,608,433
New +$5.84M
ITCI
36
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$3.96M 0.48%
273,350
-676,650
-71% -$10.4M
CFRX
37
DELISTED
ContraFect Corporation
CFRX
$3.54M 0.43%
4,375
– –
FRTX
38
DELISTED
Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
$2.58M 0.31%
+4,474
New +$2.95M
ANTH
39
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$2.01M 0.24%
1,216,403
+209,896
+21% +$361K
FLNA
40
Filana Therapeutics
FLNA
$46.4M
$1.3M 0.16%
325,509
+1
+0% +$4
OREX
41
DELISTED
Orexigen Therapeutics, Inc.
OREX
$948K 0.11%
734,976
– –
LOXO
42
DELISTED
Loxo Oncology, Inc
LOXO
$369K 0.04%
4,386
-234,000
-98% -$19.5M
IRWD icon
43
Ironwood Pharmaceuticals
IRWD
$614M
– –
-3,367,080
Closed -$44.5M
KDNY
44
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
– –
-36,953
Closed -$1.97M
ZEAL
45
DELISTED
Zealand Pharma A/S American Depositary Shares
ZEAL
– –
-1,000,000
Closed -$19.2M
1
2

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q4 2017 Portfolio in Review

As of Q4 2017, BVF Inc held 46 positions worth $830M, up 5.4% from $787M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

BVF Inc withdrew a net $37.4M in Q4 2017, closing 4 positions and reducing 10 holdings. Its most notable exit was Ironwood Pharmaceuticals, an estimated $44.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 85% a quarter earlier.

Against the trend, BVF Inc opened a new position in Syndax Pharmaceuticals worth $28.3M.

  • BVF Inc's largest Q4 2017 buy was Syndax Pharmaceuticals: 3,233,618 shares worth $28.3M.
  • BVF Inc added most to Cytokinetics in Q4 2017, an estimated $50.9M increase.
  • BVF Inc's biggest Q4 2017 reduction was AnaptysBio, cutting an estimated $57.8M.
  • BVF Inc fully exited Ironwood Pharmaceuticals in Q4 2017, selling an estimated $44.5M.
  • BVF Inc's ten largest holdings make up 61% of its $830M portfolio in Q4 2017.
  • BVF Inc opened 10 new positions and closed 4 in Q4 2017.
  • BVF Inc's portfolio value rose 5.4% quarter-over-quarter to $830M.

Based on BVF Inc's 13F filing for Q4 2017, filed 14 Feb 2018.